 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Arrowhead Promises RNAi Deal, Phase I in 2013 as Investors Voice Worries
August 16, 2012
Arrowhead Promises RNAi Deal, Phase I in 2013 as Investors Voice Worries
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Arrowhead Offers Timeline for HBV Candidate, Plans Two Phase I Trials
February 14, 2013 / Gene Silencing News - Alnylam Shares Still Flying on ATTR Results, But Not All RNAi Drug Firms Get as Big a Boost on Data
August 2, 2012 / Gene Silencing News - Arrowhead Names HBV as Next RNAi Program While It Consolidates Operations
February 16, 2012 / Gene Silencing News - Arrowhead to Move Calando Cancer Drug into Phase Ib, Reports Fiscal Q3 Results
August 11, 2011 / Gene Silencing News - Calando Aims to Complete RNAi Phase I Trial, Ink Development Partnership by Year's End
May 19, 2011 / Gene Silencing News